SynTracer™ Internalization Platform
The SynTracer™ Antibody Discovery Platform enables identification of antibodies with efficient internalization rates, providing promising candidates for Antibody Drug Conjugates (ADCs).
The SynTracer™ platform allows for:
- High-throughput endocytosis screening to identify the best internalizing antibodies
- Plug & play conjugation with a fixed DAR=2 to facilitate robust and efficient screening
- Simulation of ADC processes & MOA with high sensitivity, efficiency, and productivity
SynTracerTM Antibody Discovery Platform is able to identify the lead candidate with highest endocytosis activity, thus providing a foundation of best-in-class ADC development
Key challenges and opportunities of ADC generation
- Most current ADC-antibodies not from endocytosis screening
- The higher endocytosis activity of antibody, the higher bioactivity of ADC
- The breakthrough and the big success of DS8201 highlights a hugh opportunity for next generation of ADC development
Key features
- IgG auto-conjugating-toxin: no cell binding & endocytosis activity
- A plug-&-play IgG auto-conjugation method – DAR=2
- Simultaneously mimicking ADC endocytosis & killing process
- High sensitivity due to directly cytotoxicity
Key applications
- Candidates with high endocytosis activity: ADC generation
Technical validation: Internal validation completed and patent filed in 2021
